• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Custom Made Meals Appoints Molly Montgomery as Chief Executive Officer

    5/17/22 8:30:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LNDC alert in real time by email

    Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a middle-market private investment firm with strong experience in the food industry. Ms. Montgomery succeeds Dale Easdon, who has led the Company as CEO for the past three years and has worked closely with management to ensure a smooth transition.

    "We would like to thank Dale for his leadership and contributions in bringing CMM to the enviable position we see it occupying today," said Trey Lee, Managing Director at Stellex. "We wish him well as he embarks on his future endeavors."

    Mr. Lee added, "CMM is a fast-growing company taking advantage of consumer trends for RTC foods and the growth of the fresh perimeter at retail. In part due to Molly's contributions to the Company's commercial strategy, CMM is at a new inflection point in its growth and we believe she has the unique leadership, industry and operational expertise to execute the next stage of the company's evolution. Not only does Molly have extensive knowledge of the fresh food industry, but she also has experience implementing automation, continuous improvement, and processes that enable high-growth companies to scale."

    Ms. Montgomery has deep experience in the better-for-you food, agricultural and pharmaceutical sectors and a passion for sustainability. She currently serves as a Board Director at Wilbur-Ellis, The Wine Group and Benson Hill. Previously, Ms. Montgomery served as President & CEO and Board Director of Landec Corporation (NASDAQ:LNDC), where she led two operating businesses: Curation Foods and Lifecore Biomedical. During her 10-year tenure at Landec, Lifecore expanded into new markets and grew rapidly in both revenue and profitability. At Curation Foods, Ms. Montgomery repositioned the commodity vegetable business to a diversified, fresh business with sustainable business practices and brands that include Eat Smart® vegetable and salads, Yucatan® and Cabo Fresh® guacamole and O® Olive chef-inspired vinegar and olive oils.

    Prior to Landec, Ms. Montgomery held a variety of positions in strategy, marketing, engineering and operations within the consumer products, pharmaceutical and software industries in both large corporations as well as early-stage companies.

    "After serving as a CMM Board Director over the past year, I am thrilled to more closely align myself with the outstanding team to deliver high quality, fresh foods to our customers," said Ms. Montgomery. "In addition to an existing core offering of fresh, chef-inspired RTC products that consumers already crave, CMM continues to develop innovative offerings that provide unique, convenient meal alternatives for consumers while reducing the complexities of procurement, labor management, food safety and waste for our retail customers. With the ongoing support of Stellex, CMM will continue to invest in talent, infrastructure and automation in order to scale and meet the demand in the fast-growing fresh, RTC category."

    Ms. Montgomery holds a Bachelor of Engineering Science and Master of Engineering in Chemical Engineering from the University of Louisville and an MBA from Harvard Business School.

    About Custom Made Meals

    Custom Made Meals is a Denver-based leading manufacturer of fresh, oven-ready, value-added entrees and appetizers sold through more than 15,000 retail grocery locations nationwide. Their products include kabobs and skewers, valued-added chicken, pork, beef entrees and a variety of appetizers. More information about Custom Made Meals can be found at www.custommademeals.com.

    About Stellex Capital Management

    With offices in New York, Detroit, Pittsburgh, and London, Stellex is a private equity firm with over $2.6 billion in AUM. Stellex seeks to identify and deploy capital in opportunities that have the potential to provide stability, improvement, and growth. Portfolio companies benefit from Stellex's industry knowledge, operating capabilities, network of senior executives, strategic insight, and access to capital. Sectors of particular focus include specialty manufacturing, industrial and business services, aerospace & defense, automotive, government services, transportation, logistics and food. Additional information may be found at www.stellexcapital.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005479/en/

    Get the next $LNDC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNDC

    DatePrice TargetRatingAnalyst
    8/11/2022$14.00Mkt Perform → Outperform
    Barrington Research
    7/20/2022$13.00Overweight
    Stephens
    4/6/2022Outperform → Mkt Perform
    Barrington Research
    10/4/2021$15.00 → $14.00Buy
    Roth Capital
    7/30/2021$12.00 → $15.00Buy
    Roth Capital
    More analyst ratings

    $LNDC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Landec upgraded by Barrington Research with a new price target

    Barrington Research upgraded Landec from Mkt Perform to Outperform and set a new price target of $14.00

    8/11/22 9:23:39 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Landec with a new price target

    Stephens initiated coverage of Landec with a rating of Overweight and set a new price target of $13.00

    7/20/22 7:31:01 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec downgraded by Barrington Research

    Barrington Research downgraded Landec from Outperform to Mkt Perform

    4/6/22 9:22:55 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Schechter Joshua converted options into 9,554 shares, increasing direct ownership by 20% to 57,667 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 7:02:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calloway Nathaniel converted options into 3,981 shares, increasing direct ownership by 17% to 28,069 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:41:59 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Obus Nelson converted options into 9,554 shares, increasing direct ownership by 12% to 88,687 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:40:32 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifecore Biomedical Announces Completion of Corporate Name Change

    Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol "LFCR" Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has completed its transition to Lifecore Biomedical, including the change of its name from Landec Corporation to Lifecore Biomedical, Inc. In connection with this change, the Company's common stock is also expected to commence trading under its new Nasdaq ticker symbol "LFCR" tomorrow, N

    11/14/22 9:01:56 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022

    CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN. The Company will participate in a fireside chat on Thursday, November 17th at 8:00 AM CT. The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's investor rel

    11/10/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Expects to Change Corporate Name to Lifecore Biomedical and Ticker Symbol to "LFCR" on November 14

    CHASKA, Minn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company") today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the ticker symbol "LFCR" prior to market open on November 14, 2022. This new ticker symbol will replace the Company's current ticker symbol "LNDC," which has been used since its initial public offering in 1996. The new corporate name and ticker symbol align with the Company's ongoing strategic transformation toward its high-growth, high-value CDMO business that is focused on the development, fill and f

    11/1/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    SEC Filings

    View All

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    2/16/24 4:12:45 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Landec Corporation

    SCHEDULE 13G - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/14/24 3:39:52 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    1/12/24 4:51:33 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Leadership Updates

    Live Leadership Updates

    View All

    Custom Made Meals Appoints Molly Montgomery as Chief Executive Officer

    Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a middle-market private investment firm with strong experience in the food industry. Ms. Montgomery succeeds Dale Easdon, who has led the Company as CEO for the past three years and has worked closely with management to ensure a sm

    5/17/22 8:30:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Financials

    Live finance-specific insights

    View All

    Landec Corporation Reports First Quarter Fiscal Year 2023 Results

    Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first

    10/6/22 7:15:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T

    9/28/22 4:05:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Sets First Quarter 2023 Earnings Conference Call for October 5, 2022 at 2:00 p.m. PT

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web

    9/21/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Landec Corporation (Amendment)

    SC 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/9/24 9:59:14 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    1/4/24 4:00:21 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    8/15/23 5:07:46 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care